Business Context and Reporting Period
RXi Pharmaceuticals Corporation (also referenced as Phio Pharmaceuticals Corp. in metadata) filed a Form 8-K on December 17, 2013. The filing reports the entry into a material definitive agreement for new office and laboratory space.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or liquidity metrics. It details a new financial obligation arising from a lease agreement:
- Lease Term: 5 years, commencing April 1, 2014, and expiring March 31, 2019.
- Space: Approximately 7,581 square feet located at 257 Simarano Drive, Marlborough, Massachusetts.
- Base Rent (Year 1): $107,709.50 per annum, payable monthly.
- Rent Escalation: Approximately 3% annual increase thereafter.
- Additional Costs: Base rent includes estimated taxes and operating expenses. The Company is responsible for 11% of any excess actual taxes or expenses over estimates.
Material Changes
The filing does not provide comparative financial data against prior periods. The material change is the commitment to a new 5-year lease obligation starting in the second quarter of 2014.
Outlook and Risks
The Company has secured space for its office and laboratory operations. The primary financial risk is the fixed cost of the lease and the variable exposure to real estate taxes and operating expenses, capped at the Company's 11% pro rata share of any excess over estimates. No other risks, contingencies, or management commentary regarding future guidance are provided in this document.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can meet the $107,709.50 annual rent obligation starting April 2014.
- Confirm the total square footage requirements relative to the 7,581 sq. ft. leased to assess future expansion needs.
- Review the full Lease Agreement (Exhibit 10.1) for specific definitions of "operating expenses" and potential termination clauses.
- Check subsequent filings for any updates on the Company's financial status or changes to the lease terms.